Singapore, Aug. 18 -- Everest Medicines has announced that China's National Medical Products Administration has accepted the Biologics License Application for LEROCHOL (lerodalcibep), a third-generation PCSK9 inhibitor for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

The therapy is being developed for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol.

LEROCHOL is a small recombinant fusion protein comprising a PCSK9-binding Adnectin domain and human serum albumin. The candidate has an approximate molecular weight of 77 kDa and binds PCSK9 with picomolar affinity.

The recommended dosage is 300 mg administered subcutaneously once monthly. Everest M...